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Abstract - The urokinase (uPA)-type 
plasminogen activator receptor (uPAR) is a GPI-
anchored receptor that focuses urokinase (uPA) 
proteolytic activity on the cell surface. uPAR also 
regulates cell adhesion, migration and proliferation, 
protects from apoptosis and contributes to epithelial 
mesenchymal transition (EMT), independently of 
uPA enzymatic activity. Indeed, uPAR interacts with 
beta1, beta2 and beta3 integrins, thus regulating their 
activities. uPAR cross-talks with receptor tyrosine 
kinases through integrins and regulates cancer cell 
dormancy, proliferation and angiogenesis. Moreover, 
uPAR mediates uPA-dependent cell migration and 
chemotaxis induced by fMet-Leu-Phe (fMLF), 
through its association with fMLF-receptors (fMLF-
Rs). Further, uPAR is an adhesion receptor because 
it binds vitronectin (VN), a component of provisional 
extracellular matrix. High uPAR expression predicts 
for more aggressive disease in several cancer types 
for its ability to increase invasion and metastasis. In 
fact, uPAR has been hypothesized to be the link 
between tumor cell dormancy and proliferation that 
usually precedes the onset of metastasis. Thus, 
inhibiting uPAR could be a feasible approach to 
affect tumor growth and metastasis. 
Here, we review the more recent advances in the 
development of  uPAR-targeted anti-cancer 
therapeutic agents suitable for further optimization or 
ready for the evaluation in early clinical trials. 
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I.  INTRODUCTION 
 
 The urokinase (uPA)-mediated plasminogen 
activation system is involved in various pathologic 
processes, including angiogenesis, inflammation, wound 
healing, and metastasis [1]. 
The uPA receptor (uPAR) is anchored to the plasma 
membrane by a GPI moiety and is formed by three 
homologous domains (DI, DII, and DIII, from the N-
terminus). The uPA-binding site is located in the DI 
domain, but the full-length molecule is required for an 
efficient binding [2,3]. uPAR enhances pericellular 
proteolysis by serving as a docking site to uPA, thus 
triggering a cascade of proteolytic events that leads to the 
active degradation of extracellular matrix (ECM) 
components [4]. The crystal structure of uPAR bound to 
an antagonist peptide [2] or to the amino-terminal 
fragment (ATF) of uPA has been solved [3]. uPA is 
embedded in a central cavity and the large outer receptor 
surface is available to bind additional ligands and to 
interact with other cell surface receptors to form a 
dynamic multiprotein signaling complex [5]. Indeed, 
despite the lack of a transmembrane domain, uPAR can 
activate intracellular signaling through lateral interactions 
with other cell surface receptors, such as integrins, 
receptor tyrosine kinases, and G-protein–coupled 
chemotaxis receptors [1]. uPAR ability to regulate integrin 
activity plays a key role in cell adhesion, migration, 
proliferation, and survival [1]. Integrin-binding sites have 
been identified in uPAR domain DII (peptide D2A, 
residues 130–142) and in uPAR domain DIII (residues 
240–248). Soluble D2A abolishes uPAR-alphavbeta3 and 
uPAR-alpha5beta1 co-immunoprecipitation, indicating 
that it can bind both of these integrins; in addition, D2A 
has chemotactic activity that requires alphavbeta3 and 
activates alphavbeta3 signaling pathways [6]. The specific 
sequence identified in the uPAR domain DIII binds the 
alpha5beta1 integrin; substituting a single amino acid in 
that region (S245A) impairs uPAR binding to the purified 
integrin [7]. The interaction of alpha5beta1 integrin with 
uPAR activates integrins; then, through an “outside in” 
activation process, EGF receptor (EGFR) is recruited to 
the complex leading to ERKs activation and cell 
proliferation, thus regulating the shift from tumor cell 
dormancy to proliferation.  
uPAR is also an adhesion receptor; it binds 
vitronectin (VN), an abundant component of provisional 
ECM [8]. The X-ray structure of the ternary complex 
between uPAR, the aminoterminal fragment of uPA 
(ATF) and the somatomedin B domain of VN (SMB) has 
been recently determined [9]. There is now evidence that 
uPAR–VN interaction is entirely mediated by a composite 
epitope exposed on the DI/DII interface of uPAR 
(residues R30, W32, S56, R58, I63, S65, S88, R91, R116, 
and Q114) [10]. uPAR interactions with integrins and VN 
are positively regulated by uPA [11], and both uPA and 
VN can induce uPAR-mediated cytoskeletal 
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reorganization and cell migration [12]. uPAR can induce 
phenotypic changes consistent with hypoxia-induced 
epithelial–mesenchymal transition (EMT), through a 
direct binding to VN [8]. Abnormal uPAR levels, as 
occurring in cancer, may favour EMT through VN binding 
and RAC-1 activation, thus facilitating tumor invasion and 
metastasis [9,13].  
uPAR interaction with chemotaxis receptors for 
fMet-Leu-Phe (fMLF-Rs) is required for both uPA- and 
fMLF-dependent cell migration and occurs through a 
chemotactic domain located in the DI–DII linker region of 
uPAR, the SRSRY sequence (amino acids, 88–92) [14]. In 
fact, a soluble cleaved form of uPAR, lacking in the DI 
domain and exposing at the N-terminus the SRSRY 
sequence, is a ligand for fMLF-Rs [15].  The uPAR DI–
DII linker region is extremely sensitive to various 
proteases, including uPA; the proteolytic cleavage 
removes DI and generates a shorter uPAR form (DIIDIII-
uPAR), unable to bind both uPA and VN but, when 
exposing the SRSRY sequence (aa 88-92) at its N-
terminus, still able to interact with fMLF-Rs [1,14]. It has 
been proposed that the SRSRY sequence is masked in 
cell-surface uPAR and that uPA binding to uPAR induces 
a conformational modification causing its exposure and 
association with members of the fMLF-R family, thus 
inducing their activation and promoting chemotaxis [16]. 
We have shown that DIIDIII-uPAR promotes ovarian 
cancer cell dissemination by driving cell migration and 
angiogenesis in a protease-independent manner [17]. 
High uPAR expression predicts for more 
aggressive disease in several cancer types, for its ability to 
regulate invasion and metastasis, cancer cell survival and 
angiogenesis [18]. uPAR has been found to be a key 
player in regulating the shift between single cell tumor 
dormancy and proliferation, that usually precedes the 
onset of metastasis [19]. Indeed, circulating and bone 
marrow cancer cells express uPAR [20]; simultaneous 
uPAR and HER2/neu gene amplification on circulating 
cancer cells has also been described [21]. In gastric 
cancer, uPAR expression on cancer cells in bone marrow 
is a prospective predictor of proliferation of these cells 
and shorter patient survival [22]. Thus, ability of uPAR to 
coordinate binding and degradation of ECM with cell 
signaling makes it an attractive therapeutic target in 




II.  uPAR INHIBITION BY RNA ANTISENSE 
METHODOLOGIES 
 
Antisense technologies blocking uPAR 
expression have evolved from the classic antisense 
oligodeoxynucleotides methodologies to cell transfection 
with vectors expressing the antisense transcript 
complementary to uPAR mRNA. Antisense RNA 
technology for downregulation of uPAR expression in 
vivo has employed both plasmid and adenovirus 
constructs. In vivo, a reduction of 80% in tibial tumour 
volumes and total inhibition of pulmonary metastases 
were observed in mice injected with osteosarcoma cells 
transfected with an antisense uPAR vector [23]. A human 
glioblastoma cell line transfected with a cDNA construct 
corresponding to 300 bp of the human uPAR 5', after 
intracerebral injection in nude mice, failed to form tumors 
[24]. Injection into nude mice, through the tail vein, of 
H1299 lung cancer cells, infected with a uPAR antisense 
adenovirus construct, reduced the incidence of lung 
metastasis by 85% as compared with the control cells 
[25]. After intracranial injection, a glioblastoma cell line, 
infected with a bicistronic construct containing antisense 
sequences of uPAR and uPA in a single adenoviral vector, 
showed inhibited invasiveness and tumorigenicity; 
subcutaneous injections of bicistronic antisense constructs 
into established tumors caused their  regression [26]. 
RNA interference (RNAi) has provided new 
avenues for the treatment of cancer. RNAi is a RNA-
guided regulation of gene expression in which duplexes of 
21-nt RNAs, known as short-interfering RNAs (siRNA), 
pair with a messenger RNA (mRNA) molecule and induce 
its degradation by the RNA-induced silencing complex 
(RISC). siRNAs can also be expressed intracellularly, 
mainly through the use of plasmids containing the RNA 
pol III promoter; in this method, short hairpin RNAs 
(shRNA) can function like siRNA duplexes to inhibit gene 
expression in a sequence-specific manner. siRNAs are 
believed to be more potent inhibitors of gene expression 
with less toxicity [27]. A shRNA-based RNAi plasmid 
system has been employed for the downregulation of 
uPAR in prostate cancer, resulting in partial reduction of 
pre-established orthotopic prostate tumor in athymic male 
nude mice with no observable secondary tumor [28]. 
Intra-peritoneal injections of a siRNA expressing plasmid 
targeting both uPAR and uPA in mice with pre-
established intracranial gliomas determined tumor 
regression [29]. In malignant meningiomas, intratumoral 
injections of the same constructs  resulted in regression of 
pre-established, subcutaneous tumors in mice; the same in 
vivo study also revealed inhibition of intracranial tumor 
formation [30]. 
The cellular machinery required for siRNA 
activity in mammalian cells is the same that 
physiologically works to regulate the normal mechanisms 
of gene expression Indeed, key players in the post-
transcriptional regulation of gene expression are small 
non-coding RNAs, termed microRNAs (miRs). MiRs are 
regulatory single-strand RNAs that typically consist of 
20–23 nucleotides in length; they regulate gene expression 
by pairing with target mRNAs, thus inhibiting their 
translation and, often, inducing their degradation [31]. We 
identified three miRs, miR-146a, miR-335 and miR-622, 
regulating the expression of both uPAR and CXCR4, the 
receptor of the stroma-derived factor 1 (SDF1) 
chemokine, in AML cell lines. These miRs directly target 
the 3’untranslated region of both uPAR- and CXCR4-
mRNAs; accordingly, uPAR/CXCR4 expression was 
reduced by their overexpression in AML cells causing 
impaired migration, invasion and proliferation of 
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myelomonocytic cells. An inverse relationship between 
uPAR/CXCR4 expression and miR-146a and miR-335 
levels was also found in blasts from AML patients [32]. 
This observation could be particularly relevant for AML 
diffusion; indeed, both uPAR and CXCR4 are involved  in 
hematopoietic stem cell (HSC) trafficking [33,34]. In 
addition, both cell-surface and soluble cleaved uPAR are 
able to regulate the activity of CXCR4, by a fMLF-R-
dependent mechanism [35]. Thus, miR-146a, whose 
deletion in mouse models leads to myeloproliferative 




III.  uPAR TARGETING BY MONOCLONAL 
ANTIBODIES 
 
Recently, a novel uPAR-targeting monoclonal 
antibody (MoAb), ATN-658, has been identified and 
developed. That MoAb does not block the binding of uPA 
or VN to uPAR but inhibits migration and invasion in 
vitro and demonstrates robust anti-tumor effects in a 
number of different animal xenograft models of solid 
tumors. In these models,  anti-tumor effects of this 
humanized MoAb have been observed regardless of tumor 
histology. Indeed, beside inhibiting metastasis in vivo, as 
expected for an uPAR-targeting agent, ATN-658 is also 
able to inhibit tumor proliferation and survival by 
inhibiting many uPAR-derived signals. In fact, ATN-658 
binds the DIII domain of uPAR, close to the C-terminus of 
the receptor where are located uPAR binding regions for 
the integrin CD11b (αM), a previously identified uPAR 
ligand [36].  
We characterized a polyclonal antibody targeting 
the SRSRY sequence of the DI-DII linker region of 
uPAR; this antibody was able to block uPAR interaction 
with f-MLFRs and to inhibit uPA- and f-MLF- dependent 
cell adhesion and migration, as well as uPAR regulation 
of CXCR4 activity, thus suggesting that this region can 
represent a suitable target for new monoclonal antibodies 
in future therapeutic approaches [4,14,35]. 
 
 
IV.  uPAR TARGETING BY SMALL MOLECULES 
 
Using a target structure guided computation 
docking, 2 compounds, 2-(Pyridin-2-ylamino)-quinolin-8-
ol and 2,2'-(methylimino)di (8-quinolinol), able to inhibit 
ERK activation by destroying uPAR/alpha5beta1integrin 
association and induce tumor cell dormancy were 
identified. These two compounds, when applied in vivo, 
inhibited ERK activity and tumor growth and blocked 
metastasis in a model of head and neck carcinoma [37]. 
A small molecule (IPR-456) inhibiting uPAR/uPA 
interaction was discovered by  a virtual screening (VS) 
approach [38]. IPR-456 and its derivative IPR-803 
inhibited uPA binding to uPAR and cell invasion of breast 
MDA-MB-231 tumor cells, exerting only a little effect on 
their   migration and no effect on their adhesion [39].Two 
additional derivatives of IPR456 showed an inhibitory 
effect on cell invasion, migration and adhesion of non-
small cell lung cancer (NSCLC) cell lines. However, the 
effects on invasion of these active compounds were 
consistent with their capability to inhibit uPA and MMP 
proteolytic activity [40]. In a subsequent study, IPR-803, 
orally administered to female mice inoculated with highly 
malignant TMD-MDA-MB-231 cells in their mammary 
fat pads, impaired metastasis formation to the lungs and 
demonstrated a promising activity as a template for the 
development of anti-metastasis drugs [41].  
We used a structure-based virtual screening (SB-
VS) approach to search for small molecules targeting the 
uPAR-binding site for VN. Indeed, uPAR promotes 
metastasis by engaging VN and activating cell signaling 
pathways [13]. Two compounds, 6 and 37, selectively 
inhibited uPAR-dependent cell adhesion to VN and the 
resulting signal transduction. Both compounds targeted 
S88 and R91, key residues for uPAR binding to VN but 
also for uPAR interaction with the f-MLFRs, thus 
impairing cell migration and in vitro ECM invasion of 
several cancer cell types and representing new promising 
leads for pharmaceuticals in cancer [42].  
uPAR interactions with VN are positively 
regulated by uPA [11]; thus  IPR-803 allosterically 
inhibited also VN binding to uPAR, explaining its strong 
anti-metastatic activity [43] 
 
 
V.  uPAR INHIBITION BY SYNTHETIC PEPTIDES 
 
Peptide technologies applied to uPAR have 
employed both the classic search for antagonists of uPA 
binding to the receptor and the search for inhibitors of 
uPAR interaction with membrane partners.  
Recently, a decapeptide antagonist of uPA 
binding to uPAR was introduced. In the MDA-MB-231 
breast cancer cell line, this antagonist peptide caused p38 
activation and low ERK activation, down-regulation of 
Bcl-2 and up-regulation of Bim without Bax modulation, 
thus exerting a pro-apoptotic effect [44]. 
A crucial uPAR signaling region is the protease 
sensitive region linking DI and DII domains; its minimal 
active 88Ser-Arg-Ser-Arg-Tyr92 sequence is able to 
trigger cell migration and angiogenesis in vitro and in 
vivo, even in the form of synthetic linear Ser-Arg-Ser-
Arg-Tyr peptide (SRSRY). To inhibit this uPAR 
sequence, a family of penta-peptides carrying the S90E 
substitution in the uPAR88-92 sequence was synthetized. 
The peptide pERERY-NH2 inhibited uPAR/fMLF-R 
interaction, thus blocking migration of various tumor cell 
lines [45]. Subsequently, new tetra-peptides having the 
general formula Ac-Arg-Glu-Arg-X-NH2 (X = Phe, Tyr, 
Trp) were synthesized, and the peptide RERF also 
potently prevented in vitro and in vivo cell migration and 
invasion [46]. Recently, it was found that RERF also 
behaved as an antiangiogenic agent by inhibiting in vitro 
and in vivo responses either to uPAR88-92 or to VEGF. 
RERF prevented the recruitment of αvβ3 integrin at the 
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focal adhesions in endothelial cells exposed to VEGF, by 
forcing αvβ3 in an inactive state either directly or 
indirectly, through fMLF-Rs  [47]. Thus, N-acetylated and 
C-amidated peptide analogues with optimized properties 
for therapeutic applications were synthesized. Ac-L-Arg-
Aib-L-Arg-D-Cα(Me)Phe-NH2, named UPARANT, in 
vivo, prevented VEGF-dependent angiogenesis. Both 
excellent stability and potency make UPARANT as a 
promising new therapeutic agent for the control of 
diseases with excessive angiogenesis, such as cancer and 
inflammation [48]. 
Recently, cyclization of the Ser-Arg-Ser-Arg-Tyr 
peptide was attempted to generate a new, more stable 
peptide that could regulate uPAR88–92-dependent 
functions. Cyclized [SRSRY] peptide competed with 
fMLF for binding to fMLF-R type 1 (FPR1) and inhibited 
cell migration in a dose-dependent manner. In vivo, 
cyclized [SRSRY] peptide reduced intestinal 
inflammation impairing recruitment of inflammatory 
monocytes to the inflamed tissue and exerted an anti-
metastatic effect by reducing in vivo vascular infiltration 
by chondrosarcoma cells [49]. 
 
VI.  CONCLUSION 
 
Despite an abundance of literature demonstrating 
the importance of uPAR in the progression of most solid 
cancers, including breast, colon, prostate, pancreatic, 
ovarian, lung, and brain as well as several hematologic 
malignancies such as acute leukemia and myeloma, no 
uPAR targeting therapeutic agents have been developed or 
evaluated in cancer clinical trials to date. A number of 
antibodies that directly inhibit the binding of uPA to 
uPAR have been proposed and tested in pre-clinical 
studies but most of these have only demonstrated modest 
antitumor activity and were therefore never advanced into 
the clinic. Recently, the humanized MoAb, ATN-658, 
inhibiting both metastasis and tumor proliferation in vivo, 
has emerged as a new promising tool for starting early 
clinical trials. 
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Among small molecules, IPR-803 is a promising 
template for the development of anti-metastasis drugs, for 
its in vivo activity. Small molecules are advantageous in 
respect to biological agents; indeed, they are orally 
available, cell permeable and highly specific [50]. uPAR-
targeting small molecules  are expected to act only in cells 
with high uPAR expression, a property almost exclusive 
to cancer cells; thus, new therapies based on these 
compounds are expected to be cancer cell specific and 
minimally toxic. These treatments, rather than be directly 
cytotoxic, will block disseminated metastatic cells, 
preventing/treating overt metastasis.  
The cyclic [SRSRY] and UPARANT peptides 
are also very recent promising tools for future therapies, 
given their selective ability to target in vivo tumor 
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